Orthopedic surgery has long been the domain of small group practices – five to fifteen surgeons, built over decades, with deep roots in their regional hospital systems and patient communities. That model is now under sustained financial pressure, and private equity has arrived with a very specific offer: sell your billing operations, your real estate, your administrative overhead, and your future revenue to us, and keep operating as though nothing changed. A growing number of orthopedic groups are accepting that deal.
The transactions rarely make headlines. There is no press conference, no local news story. A group practice in the Midwest or the Southeast quietly joins a management services organization backed by a PE firm, the surgeons sign new employment agreements, and the practice continues scheduling knee replacements and rotator cuff repairs as before. The change is structural, not clinical – at least at first.
Why Orthopedics Is a Target
Orthopedic surgery generates some of the highest per-procedure revenue in outpatient medicine. Total knee and hip replacements, spinal fusions, and arthroscopic procedures carry substantial reimbursement rates from both Medicare and commercial insurers. As more of these procedures migrate from inpatient hospital settings to ambulatory surgery centers, the economics become even more favorable – lower overhead, faster throughput, and margins that hospital systems cannot easily replicate.
Private equity firms have noticed that orthopedic groups controlling their own ASCs are essentially vertically integrated businesses with recurring, high-value procedure volume. Acquiring multiple groups across a region and consolidating their administrative infrastructure – billing, credentialing, supply chain purchasing, IT – is a straightforward path to margin expansion without touching what happens in the operating room. The surgical staff stays, the patients stay, and the financial architecture changes entirely.
There is also a demographic tailwind that makes orthopedics particularly attractive to investors with five-to-seven year hold horizons. An aging population drives consistent demand for joint replacements and spine procedures. That demand is not cyclical or discretionary. A PE-backed platform can model reliable procedure volume growth simply by tracking population aging curves, and lenders are comfortable financing acquisitions against that kind of predictable revenue baseline.
The Surgeon’s Calculation
For the individual surgeon-partner approaching retirement age, the sale math is genuinely difficult to argue against. Practice equity has historically been illiquid – you sell your shares back to the group at book value when you retire, which captures almost none of the enterprise value you spent decades building. A PE transaction offers a cash payment at a multiple of EBITDA that can equal several times what a traditional partner buyout would deliver. For a senior surgeon with meaningful ownership, that difference can be measured in millions of dollars.
Younger surgeons in the same group have a more complicated position. They may receive equity in the new combined entity – a rollup platform that is worth more paper value, but only if the PE firm achieves a profitable exit through a secondary sale or public listing. They are trading certain, modest partner economics for speculative upside tied to a financial timeline they did not design and cannot control.
What Changes After the Sale
The management services organization structure that PE firms typically use is designed to navigate state corporate practice of medicine laws, which prohibit non-physicians from owning medical practices directly. The MSO owns the business assets – equipment, real estate, brand, contracts – while a physician-owned entity retains the actual medical practice. In theory, this preserves clinical independence. In practice, the MSO controls the financial levers that shape clinical behavior: staffing ratios, scheduling templates, implant vendor contracts, and which procedures get prioritized for ASC time slots.
Implant cost is a useful place to watch for post-acquisition pressure. Orthopedic implants – hip stems, knee systems, spinal hardware – represent a major variable cost in each procedure. A PE-backed platform with dozens of practices can negotiate significant volume discounts from implant manufacturers, or shift surgeons toward preferred vendors entirely. Some surgeons accept this as a reasonable business trade-off. Others find that their preferred implant systems, which they have used for years and which they believe produce better patient outcomes, are no longer on the approved list.
Staffing patterns also shift. Independent groups historically maintained experienced surgical technicians, medical assistants, and front-office staff who had often worked with the same surgeons for years. Post-acquisition cost rationalization – the more honest term for what rollup platforms do to labor costs – tends to mean higher turnover, increased reliance on per-diem staff, and thinner coverage ratios. The surgeons still in the building feel this immediately, even if patients only feel it indirectly through scheduling delays and care coordination gaps.
The pattern playing out in orthopedics is not unique to the specialty. Regional dermatology practices have moved through a nearly identical consolidation cycle, with the same MSO structures, the same partner liquidity arguments, and the same downstream tension between financial optimization and clinical discretion. Orthopedics is simply the higher-revenue version of the same thesis.
The Regulatory Blind Spot
Federal and state regulators have been slow to develop frameworks specifically addressing PE consolidation in physician specialties. Antitrust review at the FTC and DOJ has historically focused on hospital mergers and large health system combinations, not on the accumulation of smaller group practices under a single financial sponsor. A PE firm assembling fifteen orthopedic groups across three states may not trigger the same scrutiny as a hospital acquiring a competing health system, even though the market power implications in individual communities can be similar.
Some state legislatures have begun examining corporate practice of medicine enforcement more aggressively, and a handful have introduced legislation that would require greater transparency around MSO ownership structures. The enforcement reality, though, lags well behind the transaction pace. By the time a regulatory framework catches up with a specific rollup strategy, the PE firm has typically already completed its build-out and is preparing for exit.
What that exit looks like matters enormously for the surgeons who stayed. A secondary sale to a larger PE firm resets the clock and often brings a new round of cost rationalization. A strategic sale to a hospital system or insurer may resolve some of the financial pressure but introduces a different set of institutional priorities. An IPO – the outcome that would deliver the most value to surgeon-equity holders – remains rare for specialty rollups that have not achieved genuine national scale.
The orthopedic surgeons who sold three years ago are now living inside whatever that next chapter turns out to be, with employment agreements that limit their ability to leave and non-compete clauses that make starting over in the same market expensive and legally complicated. The illiquidity problem they solved at the moment of sale has simply been replaced by a different kind of constraint.
